Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.

Hematological oncology - 1 Dec 2023

Perroud Camille, Thurian Dario, Andres Martin, Künzi Arnaud, Wiedemann Gertrud, Zeerleder Sacha, Bacher Ulrike, Pabst Thomas, Banz Yara, Porret Naomi, Rebmann Ekaterina

Abstract excerpt

Until now, next generation sequencing (NGS) data has not been incorporated into any prognostic stratification of multiple myeloma (MM) and no therapeutic considerations are based upon it. In this work, we correlated NGS data with (1) therapy response and survival parameters in newly diagnosed multiple myeloma, treated by VRd * and (2) MM disease stage: newly diagnosed multiple myeloma (ndMM) versus relapsed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP Phosphohydrolases
Share to Membrane Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37452600
DOI: 10.1002/hon.3208

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.PMID 37452600Read ↗

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.Semantic proximity Read ↗

Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technologySemantic proximity Read ↗

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Semantic proximity Read ↗

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Semantic proximity Read ↗

Genetic variants as biomarkers for progression and resistance in multiple myeloma.Semantic proximity Read ↗

<em>KRAS/NRAS</em> Mutation-Associated Transcriptional Dysregulation Identifies <em>NRL</em>, <em>CREM </em>and <em>IL-6</em> as Candidate Prognostic Biomarkers in Multiple MyelomaSemantic proximity Read ↗

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaSemantic proximity Read ↗

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistanceSemantic proximity Read ↗

Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations.Semantic proximity Read ↗

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.Semantic proximity Read ↗

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the BedsideSemantic proximity Read ↗

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.